Can COVID Vaccine Makers Benefit From the Biden Administration?

In this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss the implications of President Joe Biden's administration buying an additional 200 million doses of coronavirus vaccines, split between Moderna (NASDAQ: MRNA) and the duo of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). On Feb. 11, Biden announced that deals had been finalized with the companies, although critical details of pricing were left out. The additional doses are expected to be delivered by the end of July.

Continue reading

Source Fool.com